Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7000340 | 0.86 | ALDH1A1 (0.50) | SMN1; SMN2TSHRCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7079144 | 0.86 | SMN1; SMN2 (0.45) | SMN1; SMN2TSHRCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7000103 | 0.84 | ALDH1A1 (0.53) | SMN1; SMN2TSHRCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7006943 | 0.84 | PDE5A (0.50) | SMN1; SMN2TSHRALDH1A1TP53MAPT | |
| SCHEMBL7077422 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2TSHRCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7001724 | 0.83 | TP53 (0.56) | SMN1; SMN2TSHRALDH1A1TP53MAPT | |
| SCHEMBL7077435 | 0.83 | ALDH1A1 (0.45) | SMN1; SMN2CYP2C19ALDH1A1MAPTLMNA | |
| SCHEMBL7003827 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2RXFP1LMNAL3MBTL1POLB | |
| SCHEMBL7081274 | 0.80 | LMNA (0.51) | SMN1; SMN2ALDH1A1MAPTLMNAMEN1 | |
| SCHEMBL7002396 | 0.80 | SMN1; SMN2 (0.62) | SMN1; SMN2TSHRCYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186997-A1 | 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same | ELBION AG (DE) | 2003-10-02 | — | — | US | claimed |
| US-20030186997-A1 | 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same | ELBION AG (DE) | 2003-10-02 | — | — | US | disclosed |
| EP-1311510-A1 | 2,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES WITH AN ANTICONVULSIVE ACTION AND METHODS FOR PRODUCING THE SAME | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002018387-A1 | 2,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES WITH AN ANTICONVULSIVE ACTION AND METHODS FOR PRODUCING THE SAME | ELBION AG (DE) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186997-A1 | 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same | DDO, GRIN3A, GRIK4 | SMN1; SMN2 861/4885TSHR 3213/4885CYP3A4 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.